Atlas Trials

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Clinical trial NCT05348876 · RECRUITING

Trial details

NCT number
NCT05348876
Sponsor
Bayer
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Non-metastatic Castration-resistant Prostate Cancer
Start date
2022-08-03
Primary completion
2027-04-29
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.